doi:10.2174/138920211798120763 [4] Carta MG, Loviselli A, Hardoy MC, et al
Wegovy is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
The mechanism of action of tirzepatide is distinct from older weight loss medications
SPL UNCLASSIFIED SECTION Data SPL UNCLASSIFIED SECTION Animal Data In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5 mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15 mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5 mg/kg
It also brightens the skin
Cartilage wears down, inflammation sets in, and range of motion narrows